ST Xiangxue (300147.SZ) Announces TAEST1901 Injection Receives IND Approval for Advanced Gastric Cancer

Announcement from Zhitong Finance APP: ST Xiangxue (300147.SZ) announced that its subsidiary, Xiangxue Life Sciences (Guangdong) Co., Ltd. ("Xiangxue Life Sciences"), has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The clinical registration application for the new drug TAEST1901 Injection submitted by Xiangxue Life Sciences has been granted clinical trial permission. The drug's applied indication is: for the treatment of advanced gastric cancer with HLA-A*02:01 genotype and positive expression of tumor antigen AFP.